| Sydney Adel Delgado, | |
|
1324 E Common St Ste 307, New Braunfels, TX 78130-3566 | |
| (830) 625-7310 | |
| Not Available |
| Full Name | Sydney Adel Delgado |
|---|---|
| Gender | Female |
| Speciality | Physical Therapy |
| Experience | 3 Years |
| Location | 1324 E Common St Ste 307, New Braunfels, Texas |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1164175667 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 225100000X | Physical Therapist | (* (Not Available)) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Texas Physical Therapy Specialists | 2567422538 | 176 |
News Archive
New research could have an "incredible" impact on the numbers of people being saved through the organ donor system, experts claim today. As demand for organ transplants continues to outstrip supply, a team of scientists from the University of Sunderland are hopeful they may have found a way to expand the donor pool.
Here's another potential reason to live up in the mountains. Lung cancer rates in both smokers and non-smokers are lower in higher-elevation counties in the western part of the United States, suggesting that oxygen may promote the incidence of lung cancer, according to a new study co-authored by a student at the Perelman School of Medicine at the University of Pennsylvania.
Nine months into the COVID-19 pandemic, scientists are still seeking to understand the protective immunity that develops against the causative agent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Despite the increasing need for serological tests in epidemiology, their clinical value has not been fully established. A new paper published in the Journal of Medical Virology in September 2020 describes the relationship of COVID-19 disease symptoms with the serological status over time.
Ascenta Therapeutics announced today that encouraging results from a Phase I dose-escalation study of two combination therapy regimens containing AT-101, an oral, pan-Bcl-2 inhibitor, in patients with the most malignant type of brain tumor, were described in an oral presentation at the 2009 Joint Meeting of the Society for NeuroOncology (SNO) and AANS/CNS Section on Tumors in New Orleans, Louisiana (Concurrent Session VI: Radiation Oncology, October 23, 2009; Abstract # 449).
› Verified 7 days ago
| Provider Name | Texas Physical Therapy Specialists |
|---|---|
| Provider Type | Part B Supplier - Physical/occupational Therapy Group In Private Practice |
| Provider Identifiers | NPI Number: 1689781338 PECOS PAC ID: 2567422538 Enrollment ID: O20041013001437 |
News Archive
New research could have an "incredible" impact on the numbers of people being saved through the organ donor system, experts claim today. As demand for organ transplants continues to outstrip supply, a team of scientists from the University of Sunderland are hopeful they may have found a way to expand the donor pool.
Here's another potential reason to live up in the mountains. Lung cancer rates in both smokers and non-smokers are lower in higher-elevation counties in the western part of the United States, suggesting that oxygen may promote the incidence of lung cancer, according to a new study co-authored by a student at the Perelman School of Medicine at the University of Pennsylvania.
Nine months into the COVID-19 pandemic, scientists are still seeking to understand the protective immunity that develops against the causative agent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Despite the increasing need for serological tests in epidemiology, their clinical value has not been fully established. A new paper published in the Journal of Medical Virology in September 2020 describes the relationship of COVID-19 disease symptoms with the serological status over time.
Ascenta Therapeutics announced today that encouraging results from a Phase I dose-escalation study of two combination therapy regimens containing AT-101, an oral, pan-Bcl-2 inhibitor, in patients with the most malignant type of brain tumor, were described in an oral presentation at the 2009 Joint Meeting of the Society for NeuroOncology (SNO) and AANS/CNS Section on Tumors in New Orleans, Louisiana (Concurrent Session VI: Radiation Oncology, October 23, 2009; Abstract # 449).
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Sydney Adel Delgado, 7505 N Loop 1604 E Ste 101, Live Oak, TX 78233-2604 Ph: (210) 590-4000 | Sydney Adel Delgado, 1324 E Common St Ste 307, New Braunfels, TX 78130-3566 Ph: (830) 625-7310 |
News Archive
New research could have an "incredible" impact on the numbers of people being saved through the organ donor system, experts claim today. As demand for organ transplants continues to outstrip supply, a team of scientists from the University of Sunderland are hopeful they may have found a way to expand the donor pool.
Here's another potential reason to live up in the mountains. Lung cancer rates in both smokers and non-smokers are lower in higher-elevation counties in the western part of the United States, suggesting that oxygen may promote the incidence of lung cancer, according to a new study co-authored by a student at the Perelman School of Medicine at the University of Pennsylvania.
Nine months into the COVID-19 pandemic, scientists are still seeking to understand the protective immunity that develops against the causative agent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Despite the increasing need for serological tests in epidemiology, their clinical value has not been fully established. A new paper published in the Journal of Medical Virology in September 2020 describes the relationship of COVID-19 disease symptoms with the serological status over time.
Ascenta Therapeutics announced today that encouraging results from a Phase I dose-escalation study of two combination therapy regimens containing AT-101, an oral, pan-Bcl-2 inhibitor, in patients with the most malignant type of brain tumor, were described in an oral presentation at the 2009 Joint Meeting of the Society for NeuroOncology (SNO) and AANS/CNS Section on Tumors in New Orleans, Louisiana (Concurrent Session VI: Radiation Oncology, October 23, 2009; Abstract # 449).
› Verified 7 days ago
Nancy Patten, Physical Therapist Medicare: Medicare Enrolled Practice Location: 2166 Ranch Loop Dr, New Braunfels, TX 78132 Phone: 830-237-5527 | |
Gruene Therapy Services, Pllc Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 1067 Fm 306 Ste 608, New Braunfels, TX 78130 Phone: 737-344-0245 | |
Mrs. Katie Elizabeth Halliburton, P.T. Physical Therapist Medicare: Accepting Medicare Assignments Practice Location: 1528 E Common St, Ste 23, New Braunfels, TX 78130 Phone: 830-620-4922 Fax: 830-625-1194 | |
Jessica Mendoza, DPT Physical Therapist Medicare: Accepting Medicare Assignments Practice Location: 272 Fm 306 Ste 122, New Braunfels, TX 78130 Phone: 830-500-5300 Fax: 830-500-5350 | |
Mr. Christopher M Mueller, DPT Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 821 Us Highway 81 W, New Braunfels, TX 78130 Phone: 210-912-7537 | |
Aimee Moreau Anthony, DPT Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 1324 Common St, Suite 307, New Braunfels, TX 78130 Phone: 830-625-7310 | |
Mr. Francisco Yap Jr., PT Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 2056 Sundance Pkwy Apt 7207, New Braunfels, TX 78130 Phone: 716-335-4998 |